Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food advisory committee meeting

This article was originally published in The Tan Sheet

Executive Summary

Proposed osteoarthritis health claims for glucosamine & chondroitin sulfate, as well as crystalline glucosamine sulfate are the topic of the next meeting of CFSAN's Food Advisory Committee, scheduled for June 7 and 8. A portion of the meeting involving the Dietary Supplement Subcommittee will gather information and advice related to the etiology of osteoarthritis and the relevance of scientific studies cited in the petitions. The meeting will be held at the Bethesda Marriott, 5150 Pooks Hill Road. Weider filed a petition with FDA in mid-2003 seeking a qualified health claim to link products containing glucosamine and/or chondroitin sulfate with a reduced risk of osetoarthritis (1"The Tan Sheet" June 16, 2003, p. 17)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel